Emerging mechanistic evidence highlights B7-H3’s role of B7-H3 in promoting tumor immune evasion and facilitating RMS progression, thereby strengthening the rationale for developing B7-H3-directed immunotherapies for RMS treatment [72]. This evidence concerns the gene CD276 and neoplasm.